CA2492037A1 - Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase - Google Patents

Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase Download PDF

Info

Publication number
CA2492037A1
CA2492037A1 CA002492037A CA2492037A CA2492037A1 CA 2492037 A1 CA2492037 A1 CA 2492037A1 CA 002492037 A CA002492037 A CA 002492037A CA 2492037 A CA2492037 A CA 2492037A CA 2492037 A1 CA2492037 A1 CA 2492037A1
Authority
CA
Canada
Prior art keywords
amino
oxo
quinazoline
chloro
buten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002492037A
Other languages
French (fr)
Inventor
Michel Pairet
Christopher John Montague Meade
Michael P. Pieper
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2492037A1 publication Critical patent/CA2492037A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase and to methods for the production of said compositions and the use thereof for therapy of respiratory tract diseases.

Description

" CA 02492037 2005-O1-07 WO 2004!004775 1 PCT/EP2003/006788 81273pct.211 Novel drug compositions based on novel anticholinergics and inhibitors of EGFR-kinase The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory complaints.
Description of the invention The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory complaints.
Surprisingly, an unexpectedly beneficial therapeutic effect, particularly a synergistic effect can be observed in the treatment of inflammatory andlor obstructive diseases of the respiratory tract if one or more, preferably one, anticholinergic of formula 1 is used with one or more, preferably one, EGFR-kinase inhibitor 2. In view of this synergistic effect the pharmaceutical combinations according to the invention can be used in smaller doses than would be the case with the individual compounds used in monotherapy in the usual way.
The combinations of active substances according to the invention are surprisingly characterised both by a rapid onset of activity and also by a long-lasting duration of activity. This is very important to the patient's feeling of well-being, as on the one hand they experience a rapid improvement in their condition once the combination has been administered and on the other hand the drug need only be taken once a day, thanks to its long-lasting effects.
These effects are observed both when the active substances are administered simultaneously within a single active substance formulation and also when the two active substances are administered successively in separate formulations. It is preferable according to the invention to administer the two active ingredients simultaneously in a single formulation.
Within the scope of the present invention the anticholinergics used are the salts of formula 1 O

wherein X - denotes an anion with a single negative charge, preferably an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate.
Preferably, the salts of formula 1 are used wherein X - denotes an anion with a single negative charge selected from the group consisting of chloride, bromide, 4-toluenesulphonate and methanesulphonate, preferably bromide.
Most preferably, the salts of formula 1 are used wherein X - denotes an anion with a single negative charge selected from the group consisting of chloride, bromide and methanesulphonate, preferably bromide.
Particularly preferred according to the invention is the salt of formula 1 wherein X - denotes bromide.
The salts of formula 1 are known from International Patent Application WO
02/32899.
Within the scope of the present patent application, an explicit reference to the pharmacologically active cation of formula Met+~Me -N X

r WO 2004/004775 3 PCT/EP20031006788 Men+~Me N
O H
O O
Me can be recognised by the use of the designation 1'. Any reference to compounds 1 naturally includes a reference to the cation 1'.
Within the scope of the present invention the term EGFR kinase inhibitors (hereinafter 2) preferably denotes those compounds which are selected from among 4-[(3-chloro-4-fluoro-phenyl)amino]-7-(2-(4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)am inoJ-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-((3-chloro-4-fluorophenyl)aminoJ-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-~[4-(N, N-diethylam ino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-G-{[4-(N, N-dimethylam ino)-1-oxo-2-buten-1-y1]am ino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-~N-[2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morphol in-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-~[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)aminoJ-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-.. CA 02492037 2005-O1-07 quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N, N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl}am ino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-m ethyl-am ino]-1-oxo-2-buten-1-yl}am ino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-am ino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yfoxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]am ino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-{[4-(N, N-dim ethylam ino)-1-oxo-2-buten-1-yl]am ino)-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-((3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 4-j(3-chloro-4-fluorophenyl)aminoJ-7-[3-(morpholin-4-yl)-propyloxy]-6-[(vinyl-carbonyl)amino]-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidin, 3-cyano-4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxy-quinoline, 4-{[3-chloro-4-(3 fluoro-benzyloxy)-phenyl]amino}-6-(5-{[(2-methansulfonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline, Cetuximab, Trastuzumab, ABX-EGF and Mab ICR-62.
Preferred EGFR kinase inhibitors 2 are selected from among the group consisting of 4-[(3-chloro-4-fluoro-phenyl)amino]-7-(2-{4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yip-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-((3-chloro-4-fluoro-phenyl)aminoJ-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-((vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-(2,2-dimethyl-6-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-{[4-(N, N-diethylam ino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-((4-{N-[2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)am ino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)am ino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]-amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((S)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-bis-(2-m ethoxy-ethyl)-am ino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-am ino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-ffuorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-fluoropheny!)amino]-6-({4-(N-(2-methoxy-ethyl)-N-methyl-am ino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-([4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)am ino]-6-{[4-(N, N-dimethy!amino)-1-oxo-2-buten-1-yl]am ino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine or 4-[(3-chloro-4-fluoropheny!)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline.
Particularly preferred are the EGFR kinase inhibitors 2 selected from the group consisting of 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)am ino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-(2-{4-[(S )-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-(2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbony!)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopropylmethoxy-quinazoline and 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline.
Any reference to the abovementioned EGFR kinase inhibitors 2 also includes within the scope of the present invention a reference to any pharmacologically acceptable acid addition salts thereof which may exist.
By physiologically or pharmacologically acceptable acid addition salts which may be formed from 2 are meant according to the invention pharmaceutically acceptable salts which are selected from the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or malefic acid. According to the invention, the salts of the compounds 2 selected from among the salts of acetic acid, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid and methanesulphonic acid are preferred.
The pharmaceutical combinations of 1 and 2 according to the invention are preferably administered by inhalation. Suitable inhalable powders packed into suitable capsules (inhalettes) may be administered using suitable powder inhalers. Alternatively, the drug may be inhaled by the application of suitable inhalation aerosols. These also include powdered inhalation aerosols which contain HFA134a, HFA227 or a mixture thereof as propellant gas, for example. The drug may also be inhaled using suitable solutions of the pharmaceutical combination consisting of 1 and 2.
In one aspect, therefore, the invention relates to a pharmaceutical composition which contains a combination of 1 and 2.
In another aspect the present invention relates to a pharmaceutical composition which contains one or more salts 1 and one or more compounds 2, optionally in the form of their solvates or hydrates. The active substances may be combined in a single preparation or contained in two separate formulations. Pharmaceutical compositions which contain the active substances 1 and 2 in a single preparation are preferred according to the invention.
In another aspect the present invention relates to a pharmaceutical composition which contains, in addition to therapeutically effective quantities of 1 and 2, a pharmaceutically acceptable carrier or excipient. In another particularly preferred aspect the present invention relates to a pharmaceutical composition which does not contain any pharmaceutically acceptable excipient in addition to therapeutically effective quantities of 1 and 2.
The present invention also relates to the use of 1 and 2 for preparing a pharmaceutical composition containing therapeutically effective quantities of and 2 for treating inflammatory or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD), as well as complications thereof such as pulmonary hypertension, as well as allergic WO 20041004775 $ PCT/EP2003/006788 and non-allergic rhinitis, provided that treatment with EGFR kinase inhibitors is not contraindicated from a therapeutic point of view, by simultaneous or successive administration.
The present invention also relates to the simultaneous or successive use of therapeutically effective doses of the combination of the above pharmaceutical compositions 1 and 2 for treating inflammatory and/or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD), as well as complications thereof such as pulmonary hypertension, as well as allergic and non-allergic rhinitis, provided that treatment with EGFR kinase inhibitors is not contraindicated from a therapeutic point of view, by simultaneous or successive adm inistration.
In the active substance combinations of 1 and 2 according to the invention, ingredients 1 and 2 may be present in the form of their enantiomers, mixtures of enantiomers or in the form of racemates.
The proportions in which the two active substances 1 and 2 may be used in the active substance combinations according to the invention are variable.
Active substances 1 and 2 may possibly be present in the form of their solvates or hydrates. Depending on the choice of the compounds 1 and 2, the weight ratios which may be used within the scope of the present invention vary on the basis of the different molecular weights of the various compounds and their different potencies. As a rule, the pharmaceutical combinations according to the invention may contain compounds 1 and 2 in ratios by weight ranging from 1:300 to 60:1, preferably from 1:200 to 30:1.
In the particularly preferred pharmaceutical combinations which contain in addition to a compound of formula 1 a compound selected from among 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-((3-chloro-4-fluoro-phenyl)amino]-7-(4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chlaro-4-fluoro-pheny!)amino]-7-(2-{4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N-[2-(ethoxycarbonyl)-WO 2004/004775 g PCT/EP2003/006788 ethyl]-N-[(ethoxycarbonyl)methyl]am ino}-1-oxo-2-buten-1-yl)am ino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline and 4-((3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline as EGFR kinase inhibitors 2, the weight ratios of 1 to 2 are preferably in a range wherein the cation 1' and 2 are present in proportions ranging from 1:180 to 15:1, more preferably from 1:150 to 3:1, most preferably from 1:100 to 1:30.
The pharmaceutical compositions according to the invention containing the combinations of 1 and 2 are normally used so that 1 and 2 may be present together in doses from 1000 to 100,000 pg, preferably from 1500 to 50,000 Ng, more preferably from 2000 to 10,OOONg, even more preferably from 2500 to 7500Ng per single dose. For example, combinations of 1 and 2 according to the invention contain an amount of 1' and EGFR kinase inhibitors 2 such that the total dosage per single dose is 2500Ng, 2550Ng, 2600Ng, 2650Ng, 2700pg, 2750pg, 2800Ng, 2850Ng, 2900pg, 2950Ng, 3000pg, 3050pg, 3100Ng, 3150Ng, 3200pg, 3250pg, 3300Ng, 3350Ng, 3400Ng, 3450pg, 3500pg, 3550Ng, 3600Ng, 3650Ng, 3700Ng, 3750pg, 3800Ng, 3850Ng, 3900pg, 3950Ng, 4000Ng, 4050Ng, 4100Ng, 4150Ng, 4200Ng, 4250Ng, 4300Ng, 4350Ng, 4400Ng, 4450Ng, 4500Ng, 4550Ng, 4600Ng, 4650Ng, 4700Ng, 4750pg, 4800Ng, 4850Ng, 4900Ng, 4950pg, 5000Ng, 5050Ng, 5100Ng, 5150pg, 5200Ng, 5250pg, 5300Ng, 5350Ng, 5400Ng, 5450pg, 5500Ng, 5550Ng, 5600pg, 5650pg, 5700pg, 5750Ng, 5800Ng, 5850Ng, 5900pg, 5950Ng, 6000Ng, 6050Ng, 6100Ng, 6150Ng, 6200pg, 6250Ng, 6300pg, 6350Ng, 6400pg, 6450Ng, 6500pg, 6550Ng, 6600Ng, 6650Ng, 6700Ng, 6750pg, 6800Ng, 6850Ng, 6900Ng, 6950pg, 7000pg, 7050pg, 7100pg, 7150Ng, 7200Ng, 7250Ng, 7300Ng, 7350Ng, 7400Ng, 7450pg, 7500pg or the like. These proposed dosages per single dose are not to be regarded as being restricted to the numerical values explicitly mentioned but are merely disclosed by way of example. Obviously, dosages which fluctuate around these values within a range of about +/- 25Ng are also covered by the values mentioned by way of example. In these dosage ranges the active substances 1' and 2 may be present in the weight ratios described above.
For example and without restricting the scope of the invention thereto, the combinations of 1 and 2 according to the invention may contain an amount of 1' and EGFR kinase inhibitor 2 such that 16.5Ng of 1' and 2500pg of 2, WO 2004!004775 1 Q PCT/EP20031006788 16.5Ng of 1' and 3000Ng of 2, 16.5Ng of 1' and 3500Ng of 2, 16.5pg of 1' and 40001ag of 2, 16.5Ng of 1' and 4500Ng of 2, 16.5Ng of 1' and 5000Ng of 2, 16.5pg of 1' and 5500Ng of 2, 16.5pg of 1' and 6000Ng of 2, 16.5pg of 1' and 6500Ng of 2, 16.5Ng of 1' and 70001ag of 2, 33,1 Ng of 1' and 2500Ng of 2, 33.1 Ng of 1' and 3000Ng of 2, 33.1 Ng of 1' and 3500pg of 2, 33.1 lag of 1' and 4000pg of 2, 33.1 hg of 1' and 4500pg of 2, 33.1 Ng of 1' and 5000Ng of 2, 33.1 hg of 1' and 5500Ng of 2, 33.1 Ng of 1' and 6000Ng of 2, 33.1 IJg of 1' and 6500Ng of 2, 33.1 Ng of 1' and 7000pg of 2, 49.5Ng of 1' and 2500Ng of 2, 49.51ag of 1' and 3000Ng of 2, 49.51ag of 1' and 3500Ng of 2, 49.51ag of 1' and 4000Ng of 2, 49.5Ng of 1' and 4500pg of 2, 49.5Ng of 1' and 5000Ng of 2, 49.5pg of 1' and 5500Ng of 2, 49.5Ng of 1' and 60001ag of 2, 49.5pg of 1' and 6500pg of 2, 49.5pg of 1' and 7000pg of 2, 82.6pg of 1' and 2500Ng of 2, 82.6pg of 1' and 3000pg of 2, 82.61Jg of 1' and 3500pg of 2, 82.6Ng of 1' and 4000pg of _2, 82.6pg of 1' and 4500pg of 2, 82.6Ng of 1' and 5000Ng of 2, 82.6pg of 1' and 55001ag of 2, 82.6Ng of 1' and 6000pg of 2, 82.6pg of 1' and 6500Ng _of _2, 82.6Ng of 1' and 7000pg of 2, 165.1 )ag of 1' and 2500Ng of 2, 165.1 hg of _1' and 3000Ng of 2, 165.1 hg of 1' and 3500Ng of 2, 165.1 hg of 1' and 4000Ng of 2, 165.1 lag of 1' and 4500pg of 2, 165.1 Ng of 1' and 5000pg of _2, 165.1 hg of _1' and 5500Ng of 2, 165.1 leg of 1' and 60001~g of 2, 165.1 hg of _1' and 6500Ng of 2, 165.1 lag of 1' and 70001~g of 2, 206.4Ng of 1' and 2500pg of _2, 206.4Ng of _1' and 3000trg of 2, 206.4pg of 1' and 35001~g of 2, 206.4Ng of _1' and 40001~g of 2, 206.4Ng of 1' and 4500Ng of 2, 206.41~g of 1' and 5000Ng of _2, 206.4pg of 1' and 5500Ng of 2, 206.41~g of 1' and 60001~g of 2, 206.4Ng - _ -of _1' and 65001~g of 2, 206.4Ng of 1' and 70001ag of 2, 412.8lag of 1' and 2500pg of _2, 412.8Ng of 1' and 30001ag of 2, 412.8Ng of 1' and 3500Ng of _2, 412.8Ng of _1' and 4000Ng of 2, 412.81ag of 1' and 45001~g of 2, 412.8pg of _1' and 5000pg of 2, 412.8Ng of 1' and 5500Ng of 2, 412.81~g of 1' and 6000pg of 2, 412.8Ng of 1' and 6500Ng of 2 or 412.81~g of 1' and 7000Ng of 2 are administered per single dose.
If the active substance combination wherein 1 denotes the bromide is used as the preferred combination of 1 and 2 according to the invention, the quantities of active substances 1' and 2 administered per single dose as specified by way of example correspond to the following quantities of 1 and 2 administered per single dose: 201~g of 1 and 25001~g of 2, 201ag of 1 and 3000Ng of 2, 20Ng of _1 and 3500pg of 2, 201~g of 1 and 4000Ng of 2, 20Ng of 1 and 4500Ng of 2, 20pg _ _of _1 and 5000Ng of 2, 20Ng of 1 and 5500Ng of 2, 20Ng of 1 and 6000Ng of 2, 20)ag _ _of 1 and 6500Ng of 2, 201~g of 1 and 7000pg of 2, 40pg of 1 and 2500pg of 2, 40Ng of 1 and 3000pg of 2, 40Ng of 1 and 3500Ng of 2, 40Ng of 1 and 4000pg of 2, 40pg of 1 and 4500Ng of 2, 40Ng of 1 and 5000pg of 2, 40Ng of 1 and 5500Ng of 2, 40pg of 1 and 6000pg of 2, 40Ng of 1 and 6500pg of 2, 40Ng of 1 and 7000Ng of 2, 60pg of 1 and 2500pg of 2, 60pg of 1 and 3000pg of 2, 60Ng of 1 and 3500pg of 2, 60Ng of 1 and 4000Ng of 2, 60Ng of 1 and 4500Ng of 2, 60Ng of 1 and 5000Ng of 2, 60pg of 1 and 5500Ng of 2, 60Ng of 1 and 6000pg of 2, 60pg of 1 and 6500pg of 2, 60Ng of 1 and 7000Ng of 2, 100pg of 1 and 2500Ng of 2, 100pg of 1 and 3000Ng of 2, 100Ng of 1 and 3500pg of 2, 100pg of 1 and 4000Ng of 2, 100Ng of 1 and 4500Ng of 2, 100Ng of 1 and 5000pg of 2, 100pg of 1 and 5500Ng of 2, 100Ng of 1 and 6000Ng of 2, 1 OOpg of 1 and 6500Ng of 2, 100Ng of 1 and 7000pg of 2, 200Ng of 1 and 2500pg of 2, 200Ng of 1 and 3000pg of 2, 200Ng of 1 and 3500Ng of 2, 200pg of 1 and 4000Ng of 2, 200Ng of 1 and 4500pg of 2, 200Ng of 1 and 5000Ng of 2, 200Ng of 1 and 5500pg of 2, 200Ng of 1 and 6000Ng of 2, 200Ng of 1 and 6500Ng of 2, 200Ng of 1 and 7000pg of 2, 250Ng of 1 and 2500Ng of 2, 250Ng of 1 and 3000pg of 2, 250Ng of 1 and 3500pg of 2, 250Ng of 1 and 4000Ng of 2, 250Ng of 1 and 4500pg of 2, 250Ng of 1 and 5000Ng of 2, 250Ng of 1 and 5500Ng of 2, 250pg of 1 and 6000pg of 2, 250Ng of 1 and 6500Ng of 2 or 250pg of 1 and 7000Ng of 2, 500Ng of 1 and 2500Ng of 2, 500Ng of 1 and 3000Ng of 2, 500Ng of 1 and 3500Ng of 2, 500Ng of 1 and 4000Ng of 2, 500pg of 1 and 4500Ng of 2, 500Ng of 1 and 5000pg of 2, 500Ng of 1 and 5500pg of 2, 500pg of 1 and 6000pg of 2, 500Ng of 1 and 6500Ng of 2 or 500Ng of 1 and 7000Ng of 2.
The active substance combinations of 1 and 2 according to the invention are preferably administered by inhalation. For this purpose, ingredients 1 and 2 have to be made available in forms suitable for inhalation. Inhalable preparations include inhalable powders, propellant-containing metering aerosols or propellant-free inhalable solutions. Inhalable powders according to the invention containing the combination of active substances 1 and 2 may consist of the active substances on their own or of a mixture of the active substances with physiologically acceptable excipients. Within the scope of the present invention, the term propellant-free inhalable solutions also includes concentrates or sterile inhalable solutions ready for use. The preparations according to the invention may contain the combination of active substances 1 and 2 either together in one formulation or in two or three separate formulations. These formulations which may be used within the scope of the present invention are described in more detail in the next part of the specification.
A) Inhalable powder containing the combinations of active substances 1 and 2 according to the invention:
The inhalable powders according to the invention may contain 1 and 2 either on their own or in admixture with suitable physiologically acceptable excipients.
If the active substances 1 and 2 are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention:
monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Within the scope of the inhalable powders according to the invention the excipients have a maximum average particle size of up to 250pm, preferably between 10 and 150Nm, most preferably between 15 and 80pm. It may sometimes seem appropriate to add finer excipient fractions with an average particle size of 1 to 9Nm to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substance 1 and 2, preferably with an average particle size of 0.5 to 10pm, more preferably from 1 to 6pm, is added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and by finally mixing the ingredients together are known from the prior art. The inhalable powders according to the invention may be prepared and administered either in the form of a single powder mixture which contains both 1 and 2 or in the form of separate inhalable powders which contain only 1 or 2.

The inhalable powders according to the invention may be administered using inhalers known from the prior art. Inhalable powders according to the invention which contain a physiologically acceptable excipient in addition to and 2 may be administered, for example, by means of inhalers which deliver a single dose from a supply using a measuring chamber as described in US 4570630A, or by other means as described in DE 36 25 685 A. Preferably, the inhalable powders according to the invention which contain physiologically acceptable excipients in addition to 1 and 2 are packed into capsules (to produce so-called inhalettes) which are used in inhalers as described, for example, in WO 94/28958.
A particularly preferred inhaler for using the pharmaceutical combination according to the invention in inhalettes is shown in Figure 1.
This inhaler (Handyhaler) for inhaling powdered pharmaceutical compositions from capsules is characterised by a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring 8, and a mouthpiece 12 which is connected to the housing 1, the deck 3 and a cover 11 via a spindle 10 to enable it to be flipped open or shut, as well as air through-holes 13 for adjusting the flow resistance.
If the inhalable powders according to the invention are to be packed into capsules (inhalettes) for the preferred use described above, the quantities packed into each capsule should be 1 to 50mg, preferably 3 to 45mg, more particularly 5 to 40mg of inhalable powder per capsule. These capsules contain, according to the invention, either together or separately, the doses of 1' and 2 mentioned hereinbefore for each single dose.
B) Propellant gas-driven inhalation aerosols containing the combinations of active substances 1 and 2 according to the invention:
Inhalation aerosols containing propellant gas according to the invention may contain 1 and 2 dissolved in the propellant gas or in dispersed form. 1 and 2 may be present in separate formulations or in a single preparation, in which 1 and 2 are either both dissolved, both dispersed or only one component is dissolved and the other is dispersed. The propellant gases which may be WO 2004/004775 14 PCTlEP20031006788 used to prepare the inhalation aerosols according to the invention are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated andlor fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The propellant gases mentioned above may be used on their own or in mixtures thereof. Particularly preferred propellant gases are halogenated alkane derivatives selected from TG11, TG12, TG134a and TG227. Of the abovementioned halogenated hydrocarbons, TG 134a ( 1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof are preferred according to the invention.
The propellant-driven inhalation aerosols according to the invention may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.
The inhalation aerosols containing propellant gas according to the invention may contain up to 5 wt.-% of active substance 1 and/or 2. Aerosols according to the invention contain, for example, 0.002 to 5 wt.-°l°, 0.01 to 3 wt.-%, 0.015 to 2 wt.-%, 0.1 to 2 wt.-%, 0.5 to 2 wt.-% or 0.5 to 1 wt.-% of active substance 1 and/or 2.
If the active substances 1 and/or 2 are present in dispersed form, the particles of active substance preferably have an average particle size of up to 10~m, preferably from 0.1 to 5~m, more preferably from 1 to 5~m.
The propellant-driven inhalation aerosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers). Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of propellant-driven aerosols as hereinbefore described combined with one or more inhalers suitable for administering these aerosols. In addition, the present invention relates to inhalers which are characterised in that they contain the propellant gas-containing aerosols described above according to the invention. The present invention also relates to cartridges which are fitted with a suitable valve and can be used in a suitable inhaler and which contain one of the above-mentioned propellant gas-containing inhalation aerosols according to the invention. Suitable cartridges and methods of filling these cartridges with the inhalable aerosols containing propellant gas according to the invention are known from the prior art.
C) Propellant-free inhalable solutions or suspensions containing the combinations of active substances 1 and 2 according to the invention:
It is particularly preferred to use the active substance combination according to the invention in the form of propellant free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a m fixture of water and ethanol. The relative proportion of ethanol compared with water is not limited but the maximum is up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume.
The remainder of the volume is made up of water. The solutions or suspensions containing 1 and 2, separately or together, are adjusted to a pH
of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of particularly suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, malefic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example.
According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.
According to the invention, the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent is unnecessary in the present formulation. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100m1, preferably less than 50mg/100m1, more preferably less than 20mg/100m1. Generally, inhalable WO 2004!004775 16 PCT/EP2003/006788 solutions in which the content of sodium edetate is from 0 to 10mg/100m) are preferred.
Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions according to the invention. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols -particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the pharmacologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art. The additives also include physiologically acceptable salts such as sodium chloride as isotonic agents.
The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.
Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentioned above are preferably present in concentrations of up to 50mg/100m1, more preferably between 5 and 20mg/100m1.

Preferred formulations contain, in addition to the solvent water and the combination of active substances 1 and 2, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no sodium edetate is present.
The propellant-free inhalable solutions according to the invention are administered in particular using inhalers of the kind which are capable of nebulising a small amount of a liquid formulation in the required therapeutic dose within a few seconds to produce an aerosol suitable for therapeutic inhalation. Within the scope of the present invention, preferred nebulisers are those in which a quantity of less than 100~,L, preferably less than 50~L, more preferably between 20 and 30~,L of active substance solution can be nebulised in preferably one spray action to form an aerosol with an average particle size of less than 20~,m, preferably less than 10~,m, in such a way that the inhalable part of the aerosol corresponds to the therapeutically effective quantity.
An apparatus of this kind for propellant-free delivery of a metered quantity of a liquid pharmaceutical composition for inhalation is described for example in International Patent Application WO 91 /14468 and also in WO 97/12687 (cf. in particular Figures 6a and 6b). The nebulisers (devices) described therein are known by the name Respimat~.
This nebuliser (Respimat~) can advantageously be used to produce the inhalable aerosols according to the invention containing the combination of active substances 1 and 2. Because of its cylindrical shape and handy size of less than 9 to 15 cm long and 2 to 4 cm wide, this device can be carried at all times by the patient. The nebuliser sprays a defined volume of the pharmaceutical formulation at high pressures through small nozzles so as to produce inhalable aerosols.
The preferred atomiser essentially consists of an upper housing part, a pump housing, a nozzle, a locking mechanism, a spring housing, a spring and a storage container, characterised by - a pump housing which is secured in the upper housing part and which comprises at one end a nozzle body with the nozzle or nozzle arrangement, - a hollow plunger with valve body, WO 2004/004775 1 g PCT/EP2003/006788 - a power takeoff flange in which the hollow plunger is secured and which is located in the upper housing part, - a locking mechanism situated in the upper housing part, - a spring housing with the spring contained therein, which is rotatably mounted on the upper housing part by means of a rotary bearing, - a lower housing part which is fitted onto the spring housing in the axial direction.
The hollow plunger with valve body corresponds to a device disclosed in 7. It projects partially into the cylinder of the pump housing and is axially movable within the cylinder. Reference is made in particular to Figures 1 to 4, especially Figure 3, and the relevant parts of the description.
The hollow plunger with valve body exerts a pressure of 5 to 60 Mpa (about 50 to 600 bar), preferably 10 to 60 Mpa (about 100 to 600 bar) on the fluid, the measured amount of active substance solution, at its high pressure end at the moment when the spring is actuated. Volumes of 10 to 50 microlitres are preferred, while volumes of 10 to 20 microlitres are particularly preferred and a volume of 15 microlitres per spray is most particularly preferred.
The valve body is preferably mounted at the end of the hollow plunger facing the valve body.
The nozzle in the nozzle body is preferably microstructured, i.e. produced by microtechnology. Microstructured valve bodies are disclosed for example in WO-94/07607; reference is hereby made to the contents of this specification, particularly Figure 1 therein and the associated description.
The nozzle body consists for example of two sheets of glass and/or silicon firmly joined together, at least one of which has one or more microstructured channels which connect the nozzle inlet end to the nozzle outlet end. At the nozzle outlet end there is at least one round or non-round opening 2 to 10 microns deep and 5 to 15 microns wide, the depth preferably being 4.5 to 6.5 microns while the length is preferably 7 to 9 microns.
In the case of a plurality of nozzle openings, preferably two, the directions of spraying of the nozzles in the nozzle body may extend parallel to one another or may be inclined relative to one another in the direction of the nozzle opening. fn a nozzle body with at least two nozzle openings at the outlet end the directions of spraying may be at an angle of 20 to 160° to one another, preferably 60 to 150°, most preferably 80 to 100°. The nozzle openings are WO 2004/004775 1 g PCT/EP2003/006788 preferably arranged at a spacing of 10 to 200 microns, more preferably at a spacing of 10 to 100 microns, most preferably 30 to 70 microns. Spacings of 50 microns are most preferred. The directions of spraying will therefore meet in the vicinity of the nozzle openings.
The liquid pharmaceutical preparation strikes the nozzle body with an entry pressure of up to 600 bar, preferably 200 to 300 bar, and is atomised into an inhalable aerosol through the nozzle openings. The preferred particle or droplet sizes of the aerosol are up to 20 microns, preferably 3 to 10 microns.
The locking mechanism contains a spring, preferably a cylindrical helical compression spring, as a store for the mechanical energy. The spring acts on the power takeoff flange as an actuating member the movement of which is determined by the position of a locking member. The travel of the power takeoff flange is precisely limited by an upper and lower stop. The spring is preferably biased, via a power step-up gear, e.g. a helical thrust gear, by an external torque which is produced when the upper housing part is rotated counter to the spring housing in the lower housing part. In this case, the upper housing part and the power takeoff flange have a single or multiple V-shaped gear.
The locking member with engaging locking surfaces is arranged in a ring around the power takeoff flange. It consists, for example, of a ring of plastic or metal which is inherently radially elastically deformable. The ring is arranged in a plane at right angles to the atomiser axis. After the biasing of the spring, the locking surtaces of the locking member move into the path of the power takeoff flange and prevent the spring from relaxing. The locking member is actuated by means of a button. The actuating button is connected or coupled to the locking member. In order to actuate the locking mechanism, the actuating button is moved parallel to the annular plane, preferably into the atomiser; this causes the deformable ring to deform in the annular plane.
Details of the construction of the locking mechanism are given in WO 97120590.
The lower housing part is pushed axially over the spring housing and covers the mounting, the drive of the spindle and the storage container for the fluid.

WO 2004/004775 2p PCT/EP2003/006788 When the atomiser is actuated the upper housing part is rotated relative to the lower housing part, the lower housing part taking the spring housing with it.
The spring is thereby compressed and biased by means of the helical thrust gear and the locking mechanism engages automatically. The angle of rotation is preferably a whole-number fraction of 360 degrees, e.g. 180 degrees. At the same time as the spring is biased, the power takeoff part in the upper housing part is moved along by a given distance, the hollow plunger is withdrawn inside the cylinder in the pump housing, as a result of which some of the fluid is sucked out of the storage container and into the high pressure chamber in front of the nozzle.
If desired, a number of exchangeable storage containers which contain the fluid to be atomised may be pushed into the atomiser one after another and used in succession. The storage container contains the aqueous aerosol preparation according to the invention.
The atomising process is initiated by pressing gently on the actuating button.
As a result, the locking mechanism opens up the path for the power takeoff member. The biased spring pushes the plunger into the cylinder of the pump housing. The fluid leaves the nozzle of the atomiser in atomised form.
Further details of construction are disclosed in PCT Applications WO 97/12683 and WO 97/20590, to which reference is hereby made.
The components of the atomiser (nebuliser) are made of a material which is suitable for its purpose. The housing of the atomiser and, if its operation permits, other parts as well, are preferably made of plastics, e.g. by injection moulding. For medicinal purposes, physiologically safe materials are used.
Figures 6a/b of WO 97/12687, to which reference is explicitly made at this point, show the nebuliser (Respimat~) which can advantageously be used for inhaling the aqueous aerosol preparations according to the invention. Figure 6a of WO 97/12687 shows a longitudinal section through the atomiser with the spring biased while Figure 6b of WO 97/12687shows a longitudinal section through the atomiser with the spring relaxed. The upper housing part (51 ) contains the pump housing (52) on the end of which is mounted the holder (53) for the atomiser nozzle. In the holder is the nozzle body (54) and a filter (55). The hollow plunger (57) fixed in the power takeoff flange (56) of the locking mechanism projects partially into the cylinder of the pump housing. At its end the hollow plunger carries the valve body (58). The hollow plunger is sealed off by means of the seal (59). Inside the upper housing part is the stop (60) on which the power takeoff flange abuts when the spring is relaxed. On the power takeoff flange is the stop (61 ) on which the power takeoff flange abuts when the spring is biased. After the biasing of the spring the locking member (62) moves between the stop (61 ) and a support (63) in the upper housing part. The actuating button (64) is connected to the locking member.
The upper housing part ends in the mouthpiece (65) and is sealed off by means of the protective cover (66) which can be placed thereon.
The spring housing (67) with compression spring (68) is rotatably mounted on the upper housing part by means of the snap-in lugs (69) and rotary bearing.
The lower housing part (70) is pushed over the spring housing. Inside the spring housing is the exchangeable storage container (71 ) for the fluid (72) which is to be atomised. The storage container is sealed off by the stopper (73) through which the hollow plunger projects into the storage container and is immersed at its end in the fluid (supply of active substance solution).
The spindle (74) for the mechanical counter is mounted in the covering of the spring housing. At the end of the spindle facing the upper housing part is the drive pinion (75). The slider (76) sits on the spindle.
The nebuliser described above is suitable for nebulising the aerosol preparations according to the invention to produce an aerosol suitable for inhalation.
If the formulation according to the invention is nebulised using the technology described above (Respimat~) the quantity delivered should correspond to a defined quantity with a tolerance of not more than 25%, preferably 20% of this amount in at least 97%, preferably at least 98% of all operations of the inhaler (spray actuations). Preferably, between 5 and 30 mg of formulation, most preferably between 5 and 20 mg of formulation are delivered as a defined mass on each actuation.
However, the formulation according to the invention may also be nebulised by means of inhalers other than those described above, e.g. jet stream inhalers.

Accordingly, in a further aspect, the invention relates to pharmaceutical formulations in the form of propellant-free inhalable solutions or suspensions as described above combined with a device suitable for administering these formulations, preferably in conjunction with the Respimat~. Preferably, the invention relates to propellant-free inhalable solutions or suspensions characterised by the combination of active substances 1 and 2 according to the invention in conjunction with the device known by the name Respimat~.
In addition, the present invention relates to the above-mentioned devices for inhalation, preferably the Respimat~, characterised in that they contain the propellant-free inhalable solutions or suspensions according to the invention as described hereinbefore.
The propellant-free inhalable solutions or suspensions according to the invention may take the form of concentrates or sterile inhalable solutions or suspensions ready for use, as well as the above-mentioned solutions and suspensions designed for use in a Respimat~. Formulations ready for use may be produced from the concentrates, for example, by the addition of isotonic saline solutions. Sterile formulations ready for use may be administered using energy-operated fixed or portable nebulisers which produce inhalable aerosols by means of ultrasound or compressed air by the Venturi principle or other principles.
Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of propellant-free inhalable solutions or suspensions as described hereinbefore which take the form of concentrates or sterile formulations ready for use, combined with a device suitable for administering these solutions, characterised in that the device is an energy-operated free-standing or portable nebuliser which produces inhalable aerosols by means of ultrasound or compressed air by the Venturi principle or other methods.

The Examples which follow serve to illustrate the present invention in more detail without restricting the scope of the invention to the following embodiments by way of example.
Starting materials In order to prepare compounds 2 mentioned within the scope of the present invention and not yet known in the art:
I.) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-{3-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-propyloxy}-6-[(vinylcarbonyl)amino]-quinazoline A mixture of 166 mg acrylic acid and 0.77 ml triethylamine in 10 ml of tetrahydrofuran is cooled to -50°C in a dry ice/acetone cooling bath and combined with a solution of 175 NI acrylic acid chloride in 4 ml of tetrahydrofuran. The reaction mixture is stirred at this temperature for 45 minutes. Then a solution of 427 mg of 6-amino-4-[(3-chloro-4-fluoro-phenyl)amino]-7-{3-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-propyloxy}-quinazoline in 10 ml of tetrahydrofuran is added dropwise within 20 minutes.
The reaction mixture is then slowly allowed to warm up to 0°C and stirred at this temperature until the reaction is complete. It is then combined with ice water whereupon a viscous precipitate is formed. This is extracted thoroughly several times with ethyl acetate/methanol. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The yellowish, resinous crude product is purified by chromatography over a silica gel column with methylene chloride/methanol (95:5) as eluant.
Yield: 148 mg (31 % of theory), Rr value: 0.45 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution = 90:10:0.1 ) Mass spectrum (ESI+): m/z = 567, 569 [M-H]+
The following compound is obtained analogously to I.):
4-((3-chloro-4-fluoro-phenyl)amino]-7-(2-{4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)am inoJ-quinazoline Rr value: 0.46 (silica gel, methylene chloride/methanol/concentrated aqueous ammonia solution = 90:10:0.1 ) Mass spectrum (ESI+): m/z = 581, 583 [M-H]+

II.) 4-[(3-chloro-4 fluoro-phenyl)amino]-7-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-6-[(vinylcarbonyl)amino]-quinazoline 0.47 ml triethylamine are added to 101 mg of acrylic acid in 5 ml of tetrahydrofuran under a nitrogen atmosphere. This mixture is cooled to about -50°C in a dry ice/acetone cooling bath and combined with 119 mg of acrylic acid chloride in 3 ml of tetrahydrofuran, whereupon a colourless precipitate is formed. The suspension is stirred for about another hour at this temperature.
Then 240 mg of 6-amino-4-[(3-chloro-4-fluoro-phenyl)amino]-7-[3-(2,2-dimethyl-6-oxo-morpholin-4-yl)-propyloxy]-quinazoline in 7 m1 of tetrahydrofuran are added dropwise at -55°C. The reaction mixture is allowed to heat up slowly to -30°C. After about an hour the dry ice/acetone cooling bath is exchanged for an ice lsodium chloride cooling bath. The reaction mixture is then allowed to come up to 0°C therein. As soon as the reaction is complete, the reaction mixture is combined with water and methylene chloride and made alkaline with sodium hydroxide solution. The aqueous phase separated off is extracted again with methylene chloride and a little methanol.
The combined organic extracts are washed with water, dried and evaporated down. A yellow resin remains which is chromatographed through a silica gel column with methylene chloride/methanol (98:2) as eluant. The desired product is stirred with a little tert.butylmethyl ether, the fine crystalline precipitate is suction filtered, washed again with tert.butylmethyl ether and dried in vacuo at 50°C.
Yield: 160 mg (60 % of theory), Rf value: 0.42 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 526, 528 [M-H]+
The following compounds are obtained analogously to II.):
(1 ) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline Rr value: 0.32 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESI+): m/z = 498, 500 [M-H]+
(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline Rr value: 0.30 (silica gel, methylene chloride/methanol = 95:5) Mass spectrum (ESl+): m/z = 550, 552 [M+Na]

WO 2004!004775 25 PCT/EP2003/006788 (3) 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline Mass spectrum (ESI+): m/z = 526, 528 [M-H]+
III.) 4-[(3-chloro-4 fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]am ino~-7-cyclopropylm ethoxy-quinazoline 0.67 ml oxalyl chloride and one drop of dimethylformamide are added at ambient temperature to a solution of 640 mg of 4-bromo-2-butenoic acid in 10 ml methylene chloride. The reaction mixture is stirred for about another half hour at ambient temperature until the development of gas has ended. The acid chloride produced is largely freed from solvent using the rotary evaporator in vacuo. Then the crude product is dissolved in 10 ml of methylene chloride and added dropwise while cooling with an ice bath to a mixture of 1.00 g of 6-amino-4-[(3-chloro-4-fluorophenyl)amino)-7-cyclopropylmethoxy-quinazoline and 1.60 ml of Hunig base in 50 ml of tetrahydrofuran. The reaction mixture is stirred for 1.5 hours in the ice bath and for a further 2 hours at ambient temperature. Then 2.90 ml of diethylamine are added and the mixture is stirred for 2.5 days at ambient temperature. For working up, the reaction mixture is filtered and the filtrate is evaporated down. The flask residue is purified by chromatography over a silica gel column with ethyl acetate/methanol (19:1 ).
Yield: 550 mg (40 % of theory) melting point: 114°C
Mass spectrum (ESI+): m/z = 498, 500 (M+H]
The following compounds are obtained analogously to III.):
(1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline Rf value: 0.53 (silica gel, ethyl acetate/methanol = 9:1 ) Mass spectrum (ESi+): m/z = 510, 512 [M-H]+
(2) 4-[(3-chloro-4 fiuorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoiine melting point: 137°C
Mass spectrum (ESI+): m/z = 470, 472 [M+H]
(3) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopropylmethoxy-quinazoline Rr value: 0.37 (silica gel, ethyl acetate/methanol = 9:1 ) Mass spectrum (ESI+): mlz = 488 [M+H]+
(4) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopentyloxy-quinazoline Rf value: 0.35 (silica gel, ethyl acetate/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 502 [M+H]+
IV.) 4-[(3-methylphenyl)amino]-6-[(4-~N-[(ethoxycarbonyl)methyl]-N-methylam ino~-1-oxo-2-buten-1-yl)amino]-7-methoxy-quinazoline 0.86 ml of oxalyl chloride and one drop of dimethylformamide are added to a solution of 842 mg of 4-bromo-2-butenoic acid in 15 ml methylene chloride at ambient temperature. The reaction mixture is stirred for about another hour at ambient temperature until the development of gas has ended. The acid chloride formed is largely freed from solvent in vacuo using the rotary evaporator. Then the crude product is taken up in 10 ml methylene chloride and added dropwise within five minutes to a mixture of 1.0 g of 6-amino-4-[(3-methylphenyl)amino]-7-methoxy-quinazoline and 2.0 ml of Hunig base in 50 ml of tetrahydrofuran while cooling with an ice bath. The reaction mixture is stirred for two hours while cooling with an ice bath and then for another two hours at ambient temperature. Then 6.7 ml Hunig base, 5.48 g sarcosine ethylester hydrochloride and 3 ml of dimethylformamide are added and the whole is stirred overnight at ambient temperature. For working up the reaction mixture is evaporated down in vacuo using the rotary evaporator and the flask residue is distributed between 75 ml ethyl acetate and 75 ml of water. The organic phase is washed with water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with methylene chloridelmethanol (20 : 1 ).
Yield: 326 mg (20 % of theory) melting point: 122-124°C
Mass spectrum (ESI+): m/z = 464 [M+H]
The following compound is obtained analogously to IV.):
4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbonyl)methyl]amino-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline _ WO 2004/004775 27 PCT/EP2003/006788 Rf value: 0.62 (aluminium oxide, cyclohexaneiethyl acetate = 1:1 ) Mass spectrum (EI): m/z = 627, 629 [M]
V.) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline 950 mg of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-~N-[(ethoxycarbonyl)methyl]-N-((R)-2-hydroxy-3-methoxy-propyl)-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline and 195 NI of methanesulphonic acid in 10 ml acetonitrile are refluxed for about four hours.
For working up the reaction mixture is cooled in a bath of ice water, combined with 75 ml ethyl acetate and 25 ml saturated sodium hydrogen carbonate solution and stirred vigorously for 10 minutes. The organic phase is separated off, washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution and dried over magnesium sulphate. The solvent is distilled off in vacuo, leaving a brownish foam.
Yield: 610 mg (69 % of theory), Rf value: 0.55 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 570, 572 [M+H]+
VI.) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline A mixture of 700 mg of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-~N-[(tert. butyloxycarbonyl)methyl]-N-((S)-2-hydroxy-prop-1-yl)-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline and 228 mg of p-toluenesulphonic acid hydrate in 20 ml of acetonitrile is refluxed for five hours. Then a further 200 mg of p-toluenesulphonic acid hydrate are added and the mixture is again refluxed for five hours. For working up the reaction mixture is evaporated to dryness. The flask residue is distributed between ethyl acetate and saturated sodium carbonate solution. The organic phase is separated off, washed with saturated sodium carbonate solution, water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. The oily residue is brought to crystallisation by stirring with 15 ml diethyl ether.
Melting point: 173-175°C
Mass spectrum (ESI+): m/z = 540, 542 [M+H]

WO 20041004775 2$ PCT/EP2003/006788 The following compounds are obtained analogously to VI.):
(1 ) 4-[(3-chloro-4 fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino}-7-cyclopropylmethoxy-quinazoline Rf value: 0.54 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI+): m/z = 540, 542 [M+H]
(2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]am ino~-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline (The reaction is carried out with methanesulphonic acid in acetonitrile) Rf value: 0.38 (silica gel, methylene chloride/methanol = 9:1 ) Mass spectrum (ESI'~): m/z = 556, 558 [M+H]+
VII.) 4-[(3-bromo-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline 90 pl methanesulphonic acid are added to 380 mg of 4-[(3-bromo-phenyl)amino]-6-(2-{N-[(tent.butyloxycarbonyl)methyl]-N-((S)-2-hydroxy-propyl)-amino-ethoxy)-7-methoxy-quinazoline in 8 ml acetonitrile. The reaction mixture is refluxed for about three hours, then another equivalent of methanesulphonic acid is added and refluxing is continued until the reaction is complete. For working up the reaction mixture is diluted with ethyl acetate and washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution. The organic phase is dried over magnesium sulphate and evaporated down in vacuo. The flask residue is stirred with diethyl ether and suction filtered. The title compound is obtained as a white solid.
Yield: 280 mg (85 % of theory), Melting point: 190°C
Mass spectrum (ESI+): m/z = 485, 487 [M-H]+
The following compound is obtained analogously to VIL):
4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline (The reaction is carried out with trifluoroacetic acid in acetonitrile) melting point: 212-213°C
Mass spectrum (ESI+): m/z = 461, 463 [M+H]+

WO 2004/004775 2g PCT/EP2003/006788 VIIL) 4-[(3-chloro-4-fluorophenyl)amino]-6-(~4-[N-(2-methoxy-ethyl)-N-methyl-am ino]-1-oxo-2-buten-1-yl}am ino)-7-cyclopropylmethoxy-quinazol ine 4.70 ml of oxalyl chloride are added dropwise to a solution of 4.50 g of bromocrotonic acid in 60 ml of methylene chloride. Then one drop of N,N-dimethylformamide is added. After about 30 minutes the development of gas has ended and the reaction mixture is evaporated down in the rotary evaporator. The crude bromocrotonic acid chloride is taken up in 30 ml methylene chloride and added dropwise to a solution of 7.00 g 4-[(3-chloro-4-fluorophenyl)amino]-6-amino-7-cyclopropylmethoxy-quinazoline and 10.20 ml Hunig base in 150 ml of tetrahydrofuran while cooling with an ice bath. The reaction mixture is stirred for about 1.5 hours while cooling with an ice bath and for a further two hours at ambient temperature. Then 5.20 g of N-(2-methoxy-ethyl)-N-methyl-amine are added and the reaction mixture is stirred overnight at ambient temperature. For working up it is diluted with methylene chloride and washed thoroughly with water. The organic phase is dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with ethyl acetate followed by ethyl acetate/methanol (19:1 ) as eluant.
Yield: 5.07 g (51 % of theory) Mass spectrum (ESI+): mlz = 512, 514 [M-H]+
Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1 ) The following compounds are obtained analogously to VIII):
(1 ) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]am ino~-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): m/z = 482, 484 [M-H]+
Rf value: 0.11 (silica gel, ethyl acetatelmethanol = 9:1 ) (2) 4-[(R)-(1-phenyl-ethyl)amino]-6-~[4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): mlz = 532 [M-H]+
Rf value: 0.40 (silica gel, ethyl acetate/methanol = 9:1 ) (3) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cycfopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 502 [M-H]+
Rf value: 0.20 (silica gel, ethyl acetate/methanol = 9:1 ) WO 2004/004775 3p PCT/EP2003/006788 (4) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}am ino)-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 488 [M-H]+
Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1 ) (5) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-am ino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 514 [M-H]+
Rf value: 0.15 (silica gel, ethyl acetate/methanol = 9:1 ) (6) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]am ino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline Mass spectrum (ESI+): m/z = 486, 488 [M+H]+
(7) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline Mass spectrum (ESI+): m/z = 486, 488 [M+H]+
Rf value: 0.45 (silica gel, methylene chloride/methanol = 5:1 ) (8) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-am ino]-1-oxo-2-buten-1-yl}am ino)-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): mlz = 528, 530 [M-H]+
Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1 ) (9) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): m/z = 508, 510 [M-H]+
melting point: 140°C
(10) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-(tetrahydrofuran-2-yl)methoxy]-quinazol ine Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
melting point: 110-112°C
(11 ) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): mlz = 500, 502 [M+H]

Rf value: 0.23 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:0.1 ) Some particularly preferred formulations according to the invention containing the two components 1 and 2 are described hereinafter without restricting the core of the invention thereto.
Formulation Examples Inhalable powders:
1) Ingredients Ng per capsule 1 '- brom ide 60 EGFR kinase inhibitor 3500 Lactose 3440 Total 7000 2) Ingredients Ng per capsule 1 '- bromide 100 EGFR kinase inhibitor 3000 Lactose 3900 Total 7000 3) Ingredients Ng per capsule 1 '- bromide 150 EGFR kinase inhibitor 5000 Lactose 4850 Total 10000

Claims (36)

Claims
1) Pharmaceutical compositions, characterised in that they contain one or more anticholinergics of formula 1 wherein X - denotes an anion with a single negative charge, preferably an anion selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, combined with one or more EGFR kinase inhibitors (2), optionally in the form of the enantiomers, mixtures of the enantiomers or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient.
2) Pharmaceutical composition according to claim 1, characterised in that the active substances 1 and 2 are present either together in a single formulation or in two separate formulations.
3) Pharmaceutical composition according to one of claims 1 and 2, characterised in that in the compounds of formula 1 X- is a negatively charged anion selected from the group consisting of chloride, bromide, p-toluenesulphonate and methanesulphonate.
4) Pharmaceutical composition according to one of claims 1 to 3, characterised in that in the compounds of formula 1 X- denotes bromide.
5) Pharmaceutical compositions according to one of claims 1 to 4, characterised in that 2 is selected from among 4-[(3-chloro-4-fluoro-phenyl)amino]-7-(2-{4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy)-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino)-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl)amino)-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl)amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino)-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino)-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl)amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline, 4-[(3-ethynyl-phenyl)amino]-6,7-bis-(2-methoxy-ethoxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)-propyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-(4-hydroxy-phenyl)-7H-pyrrolo[2,3-d]pyrimidine, 3-cyano-4-((3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-ethoxy-quinoline, 4-{[3-chloro-4-(3-fluoro-benzyloxy)-phenyl]amino}-6-(5-{[(2-methansulfonyl-ethyl)amino]methyl}-furan-2-yl)quinazoline, Cetuximab, Trastuzumab, ABX-EGF and Mab ICR-62, optionally in the form of the physiologically acceptable acid addition salts thereof.

6) Pharmaceutical composition according to one of claims 1 to 5, characterised in that 2 is selected from the group consisting of 4-[(3-chloro-4-fluoro-phenyl)amino]-7-(2-[4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-
6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-(2,2-dimethyl-6-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl)amino-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-([4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxa-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-((3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((R)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-7-methoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino)-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-((S)-2-methoxymethyl-6-oxo-morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-([4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-(N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-([4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-([4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(4-dimethylamino-cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine and 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline, optionally in the form of the physiologically acceptable acid addition salts thereof.
7) Pharmaceutical compositions according to one of claims 1 to 6, characterised in that 2 is selected from the group consisting of 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((R)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[4-((S)-6-methyl-2-oxo-morpholin-4-yl)-butyloxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-(2-{4-[(S)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluoro-phenyl)amino]-7-[2-((S)-6-methyl-2-oxo-morpholin-4-yl)-ethoxy]-6-[(vinylcarbonyl)amino]-quinazoline, 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-(N-[2-(ethoxycarbonyl)-ethyl]-N-[(ethoxycarbonyl)methyl]amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline and 4-[(3-chloro-4-fluorophenyl)amino]-6-[3-(morpholin-4-yl)-propyloxy]-7-methoxy-quinazoline, optionally in the form of the physiologically acceptable acid addition salts thereof.
8) Pharmaceutical composition according to one of claims 1 to 7, characterised in that the weight ratios of 1 to 2 are in the range from 1:300 to 60:1, preferably from 1:200 to 30:1.
9) Pharmaceutical composition according to one of claims 1 to 8, characterised in that a single administration corresponds to a dosage of the combination of active substances 1 and 2 of 1000 to 100,000µg, preferably from 1500 to 50,000µg.
10) Pharmaceutical composition according to one of claims 1 to 9, characterised in that it is in the form of a formulation suitable for inhalation.
11) Pharmaceutical composition according to claim 10, characterised in that it is a formulation selected from among inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.
12) Pharmaceutical composition according to claim 11, characterised in that it is an inhalable powder which contains 1 and 2 in admixture with suitable physiologically acceptable excipients selected from among the monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures of these excipients.
13) Inhalable powder according to claim 12, characterised in that the excipient has a maximum average particle size of up to 250µm, preferably between 10 and 150µm.
14) Pharmaceutical composition according to claim 11, characterised in that it is an inhalable powder which contains only active substances 1 and 2 as its ingredients.
15) Capsules, characterised in that they contain an inhalable powder according to claim 12, 13 or 14.
16) Pharmaceutical composition according to claim 11, characterised in that it is a propellant-containing inhalable aerosol which contains 1 and 2 in dissolved or dispersed form.
17) Propellant-containing inhalable aerosol according to claim 16, characterised in that it contains, as propellant gas, hydrocarbons such as n-propane, n-butane or isobutane or halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
18) Propellant-containing inhalable aerosol according to claim 17, characterised in that the propellant gas is TG11, TG12, TG134a, TG227 or mixtures thereof, preferably TG134a, TG227 or a mixture thereof.
19) Propellant-containing inhalable aerosol according to claim 16, 17 or 18, characterised in that it optionally contains one or more other ingredients selected from the group consisting of cosolvents, stabilisers, surfactants, antioxidants, lubricants and means for adjusting the pH.
20) Propellant-containing inhalable aerosol according to one of claims 16 to 19, characterised in that it may contain up to 5 wt.-% of active substance 1 and/or 2.
21) Pharmaceutical composition according to claim 11, characterised in that it is a propellant-free inhalable solution or suspension which contains water, ethanol or a mixture of water and ethanol as solvent.
22) Inhalable solution or suspension according to claim 21, characterised in that the pH is 2 - 7, preferably 2 -5.
23) Inhalable solution or suspension according to claim 22, characterised in that the pH is adjusted by means of an acid selected from among hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid or mixtures thereof.
24) Inhalable solution or suspension according to one of claims 21 to 23, characterised in that it optionally contains other co-solvents and/or excipients.
25) Inhalable solution or suspension according to claim 24, characterised in that it contains as co-solvents ingredients which contain hydroxyl groups or other polar groups, e.g, alcohols - particularly isopropyl alcohol, glycols particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
26) Inhalable solution or suspension according to one of claims 24 or 25, characterised in that it contains as excipients surfactants, stabilisers, complexing agents, antioxidants and/or preservatives, flavourings, pharmacologically acceptable salts and/or vitamins.
27) lnhalable solution or suspension according to claim 26, characterised in that it contains as complexing agent editic acid or a salt of editic acid, preferably sodium edetate.
28) Inhalable solution or suspension according to claim 26 or 27, characterised in that it contains, as antioxidants, compounds selected from among ascorbic acid, vitamin A, vitamin E and tocopherols.
29) Inhalable solution or suspension according to claim 26, 27 or 28, characterised in that it contains as preservatives compounds selected from cetyl pyridinium chloride, benzalkonium chloride, benzoic acid and benzoates.
30) Inhalable solution or suspension according to one of claims 24 to 29, characterised in that it contains, in addition to the active substances 1 and and the solvent, only benzalkonium chloride and sodium edetate.
31) Inhalable solution or suspension according to one of claims 24 to 29, characterised in that it contains, in addition to the active substances 1 and and the solvent, only benzalkonium chloride.
32) Inhalable solution or suspension according to one of claims 21 to 31, characterised in that it is a concentrate or a sterile ready-to-use inhalable solution or suspension.
33) Use of a capsule according to claim 15 in an inhaler, preferably in a Handyhaler.
34) Use of an inhalable solution according to one of claims 21 to 31 for nebulising in an inhaler according to WO 91/14468 or an inhaler as described in Figures 6a and 6b of WO 97/12687.
35) Use of an inhalable solution according to claim 32 for nebulising in an energy-operated free-standing or portable nebuliser which produces inhalable aerosols by means of ultrasound or compressed air according to the Venturi principle or other principles.
36) Use of a composition according to one of claims 1 to 32 for preparing a medicament for treating inflammatory and/or obstructive diseases of the respiratory tract.
CA002492037A 2002-07-09 2003-06-26 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase Abandoned CA2492037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10230751A DE10230751A1 (en) 2002-07-09 2002-07-09 New drug compositions based on new anticholinergics and EGFR kinase inhibitors
DE10230751.2 2002-07-09
PCT/EP2003/006788 WO2004004775A1 (en) 2002-07-09 2003-06-26 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase

Publications (1)

Publication Number Publication Date
CA2492037A1 true CA2492037A1 (en) 2004-01-15

Family

ID=29761746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002492037A Abandoned CA2492037A1 (en) 2002-07-09 2003-06-26 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase

Country Status (16)

Country Link
EP (2) EP1521595B1 (en)
JP (1) JP2005537250A (en)
CN (1) CN1665539A (en)
AT (1) ATE320269T1 (en)
AU (1) AU2003242771B2 (en)
BR (1) BR0312507A (en)
CA (1) CA2492037A1 (en)
DE (2) DE10230751A1 (en)
ES (1) ES2259769T3 (en)
MX (1) MXPA05000163A (en)
NZ (1) NZ538096A (en)
PL (1) PL374022A1 (en)
RU (1) RU2317828C2 (en)
TW (1) TW200520757A (en)
WO (1) WO2004004775A1 (en)
ZA (1) ZA200409676B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034809B2 (en) 2004-05-14 2011-10-11 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US8044046B2 (en) 2002-11-15 2011-10-25 Boehringer Ingelheim Pharma Gmbh & Co Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US8420809B2 (en) 2005-08-15 2013-04-16 Boehringer Ingelheim International Gmbh Process for the manufacturing of betamimetics

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002042325A2 (en) 2000-10-31 2002-05-30 Zycos Inc. Cyp1b1 nucleic acids and methods of use
PT2422786E (en) * 2004-04-22 2014-11-12 Boehringer Ingelheim Int New medicine combinations for treating respiratory diseases
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
EP2402318A1 (en) 2006-03-31 2012-01-04 Novartis AG DGAT inhibitors
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2927925A (en) * 1960-03-08 Scopine and sgopoline esters of alpha
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
SE8603252L (en) 1985-07-30 1987-01-31 Glaxo Group Ltd DEVICE FOR SUPPLYING MEDICINE TO PATIENTS
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IL107120A (en) 1992-09-29 1997-09-30 Boehringer Ingelheim Int Atomising nozzle and filter and spray generating device
DE4318455A1 (en) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Capsule holder
DE19536903C2 (en) 1995-10-04 1998-09-10 Boehringer Ingelheim Int Device for holding a fluidic component
DE19536902A1 (en) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Miniature fluid pressure generating device
DE19545226C1 (en) 1995-12-05 1997-06-19 Boehringer Ingelheim Int Locking mechanism for a spring-operated output
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
EE04748B1 (en) * 1999-06-21 2006-12-15 Boehringer Ingelheim Pharma Kg Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10050994A1 (en) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease
DE10206505A1 (en) * 2002-02-16 2003-08-28 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and EGFR kinase inhibitors
DE10203753A1 (en) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma New xanthene carboxylic acid esters, processes for their preparation and their use as medicines

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044046B2 (en) 2002-11-15 2011-10-25 Boehringer Ingelheim Pharma Gmbh & Co Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US8034809B2 (en) 2004-05-14 2011-10-11 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US8420809B2 (en) 2005-08-15 2013-04-16 Boehringer Ingelheim International Gmbh Process for the manufacturing of betamimetics

Also Published As

Publication number Publication date
ES2259769T3 (en) 2006-10-16
NZ538096A (en) 2007-04-27
AU2003242771B2 (en) 2009-07-30
MXPA05000163A (en) 2005-04-08
EP1521595B1 (en) 2006-03-15
ZA200409676B (en) 2006-05-31
WO2004004775A1 (en) 2004-01-15
ATE320269T1 (en) 2006-04-15
DE10230751A1 (en) 2004-01-22
AU2003242771A1 (en) 2004-01-23
RU2317828C2 (en) 2008-02-27
EP1658860A1 (en) 2006-05-24
JP2005537250A (en) 2005-12-08
CN1665539A (en) 2005-09-07
EP1521595A1 (en) 2005-04-13
TW200520757A (en) 2005-07-01
DE50302675D1 (en) 2006-05-11
PL374022A1 (en) 2005-09-19
RU2005103397A (en) 2006-03-20
BR0312507A (en) 2005-04-12

Similar Documents

Publication Publication Date Title
US20030158196A1 (en) Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US20050165013A1 (en) Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors
US7776315B2 (en) Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6608054B2 (en) Pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2439763C (en) Pharmaceutical compositions based on anticholinergics and pde-iv inhibitors
US20040058950A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20040024007A1 (en) Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20100310477A1 (en) Pharmaceutical compositions based on anticholingerics and additional active ingredients
CA2667543A1 (en) New pharmaceutical combinations for treatment of respiratory and gastrointestinal disorders
WO2005080338A2 (en) New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins
US20040002502A1 (en) Medicament combinations comprising heterocyclic compounds and a novel anticholinergic
US20060239935A1 (en) Compositions for inhalation
US20040048886A1 (en) Pharmaceutical compositions based on new anticholinergics and NK1 receptor antagonists
US20030203918A1 (en) Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound
CA2476127C (en) New pharmaceutical compositions based on anticholinergics and egfr kinase inhibitors
AU2003242771B2 (en) Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase
NZ536284A (en) Medicaments containing steroids and a novel anticholinergic drug
CA2492026A1 (en) New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors
CA2533791C (en) Medicaments for inhalation comprising betamimetics and an anticholinergic agent
CA2441964C (en) New pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2551900A1 (en) Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors
US20100015061A1 (en) Pharmaceutical Compositions Based on Anticholinergics and Andolast
ZA200306221B (en) Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors.
CA2430592C (en) New pharmaceutical compositions based on anticholinergics and dopamine agonists
US20050203088A1 (en) Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued